US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus U.S. Dividend ETF

30.08

-0.1224-0.41%

Volume:39

Turnover:1K

Market Cap:17.30M

PE:- -

High:30.08

Open:30.20

Low:30.08

Close:30.20

52wk High:30.69

52wk Low:24.79

Shares:575.00K

Float Shares:575.00K

Volume Ratio:0.01

T/O Rate:0.01%

Dividend:0.38

Dividend Rate:1.28%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/VUS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","market":"US","secType":"STK","nameCN":"Virtus U.S. Dividend ETF","latestPrice":30.0785,"timestamp":1788292800000,"preClose":30.2009,"halted":0,"volume":39,"delay":0,"changeRate":-0.004052859351873703,"floatShares":575004,"shares":575004,"eps":0,"marketStatus":"Pre-Mkt","change":-0.1224,"latestTime":"09-02 06:02:24 EDT","open":30.2009,"high":30.0785,"low":30.0785,"amount":1189,"amplitude":0,"askPrice":47.82,"askSize":100,"bidPrice":12.09,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788355800000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":30.0785,"sharesOutstanding":625004,"nav":30.194,"aum":17361812.51,"dividendRate":0.01277,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.2009,"preClose":30.0785,"latestTime":"16:10 EDT","volume":6,"amount":180.471,"timestamp":1788293404665,"change":0.1224,"changeRate":0.004069,"amplitude":0},"volumeRatio":0.012861099482533663},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","floatShares":575004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.012861099482533663,"shares":575004,"dividePrice":0.3841,"high":30.0785,"amplitude":0,"preClose":30.2009,"low":30.0785,"week52Low":24.79,"pbRate":"--","week52High":30.6924,"institutionHeld":0,"latestPrice":30.0785,"eps":0,"divideRate":0.01277,"volume":39,"delay":0,"ttmEps":0,"open":30.2009,"prevYearClose":25.2797,"prevWeekClose":30.2451,"prevMonthClose":30.2009,"prevQuarterClose":29.8174,"fiveDayClose":30.2294,"twentyDayClose":30.3806,"sixtyDayClose":30.0541},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VUS\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"VUS","amount":0.164,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-29","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-29"},{"date":"2026-03-20","symbol":"VUS","amount":0.2199,"announcedDate":"2026-03-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VUS\",market:\"US\",,,undefined,":[{"executeDate":"2026-03-20","recordDate":"2026-03-20","paymentDate":"2026-03-27","value":0.2199,"currency":"USD"},{"executeDate":"2026-06-22","recordDate":"2026-06-22","paymentDate":"2026-06-29","value":0.164,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VUS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VUS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661627957","title":"Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627957","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627957?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --  BOSTON, Aug.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349657/0/en/rhythm-pharmaceuticals-announces-mhlw-approval-of-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity-ho-in-japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","EC","BMI","BK4157","AVP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848797","title":"Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848797","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848797?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968000,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346041/0/en/rhythm-pharmaceuticals-announces-appointment-of-manher-aj-joshi-as-chief-medical-officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0792757196.USD","LU0786609619.USD","LU0823411888.USD","LU1267930813.SGD","LU0889566641.SGD","BK4534","LU0029864427.USD","BK4201","LU0310800379.SGD","STYL","VUS","BK4533","LU0310800965.SGD","BK4588","LU1267930227.SGD","BK4581","BK4585","NKE","LU0128525689.USD","BK4558","IE00BFXG0V08.USD","LU0052756011.USD","BK4561","LU1267930573.SGD","IE00BYQQ9H92.USD","LU0128525929.USD","BK4146","BK4566","LU1303367103.USD","EC","AVP","LU2098885051.SGD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658902819","title":"Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658902819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658902819?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --BOSTON, Aug.  11, 2026  (GLOBE NEWSWIRE) -- Rhythm Phar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342640/0/en/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-in-the-united-kingdom-for-treatment-of-obesity-and-control-of-hunger-in-patients-w.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","VUS","BMI","AVP","EC","BK4211","BK4157","UBCP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657859567","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2657859567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657859567?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  04, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338772/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","BK4201","VUS","EC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VUS\",params:#limit:6,delay:false,,,undefined,":[]}}